» Articles » PMID: 15966853

CSF Proteome: a Protein Repository for Potential Biomarker Identification

Overview
Publisher Informa Healthcare
Date 2005 Jun 22
PMID 15966853
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Proteomic analysis is not limited to the analysis of serum or tissues. Synovial, peritoneal, pericardial and cerebrospinal fluid represent unique proteomes for disease diagnosis and prognosis. In particular, cerebrospinal fluid serves as a rich source of putative biomarkers that are not solely limited to neurologic disorders. Peptides, proteolytic fragments and antibodies are capable of crossing the blood-brain barrier, thus providing a repository of pathologic information. Proteomic technologies such as immunoblotting, isoelectric focusing, 2D gel electrophoresis and mass spectrometry have proven useful for deciphering this unique proteome. Cerebrospinal fluid proteins are generally less abundant than their corresponding serum counterparts, necessitating the development and use of sensitive analytical techniques. This review highlights some of the promising areas of cerebrospinal fluid proteomic research and their clinical applications.

Citing Articles

Exploratory profiling of metabolites in cerebrospinal fluid using a commercially available targeted LC-MS based metabolomics kit to discriminate leptomeningeal metastasis.

Jang S, Gwak H, Lee K, Lee J, Kim K, Kim J Cancer Metab. 2025; 13(1):2.

PMID: 39838492 PMC: 11748265. DOI: 10.1186/s40170-024-00367-x.


Multiomics and blood-based biomarkers of moyamoya disease: protocol of Moyamoya Omics Atlas (MOYAOMICS).

Ge P, Yin Z, Tao C, Zeng C, Yu X, Lei S Chin Neurosurg J. 2024; 10(1):5.

PMID: 38326922 PMC: 10851534. DOI: 10.1186/s41016-024-00358-3.


Temporal proteomics of human cerebrospinal fluid after severe traumatic brain injury.

Shultz S, Shah A, Huang C, Dill L, Schittenhelm R, Morganti-Kossmann M J Neuroinflammation. 2022; 19(1):291.

PMID: 36482407 PMC: 9730674. DOI: 10.1186/s12974-022-02654-0.


Predictive Modeling of Alzheimer's and Parkinson's Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid.

Hwangbo N, Zhang X, Raftery D, Gu H, Hu S, Montine T Metabolites. 2022; 12(4).

PMID: 35448464 PMC: 9029812. DOI: 10.3390/metabo12040277.


Experimental Assessment of Leptomeningeal Metastasis Diagnosis in Medulloblastoma Using Cerebrospinal Fluid Metabolomic Profiles.

Im J, Yoo B, Lee J, Lee K, Kim K, Kim J Metabolites. 2021; 11(12).

PMID: 34940608 PMC: 8708677. DOI: 10.3390/metabo11120851.